The Argentina Lateral Flow Assays Market was valued at $13.3 Million in 2025 and projected to reach to $17 Million by 2030, representing a compound annual growth rate of 5.0%. Argentina's lateral flow assays market demonstrates steady growth potential as healthcare providers increasingly prioritize point-of-care diagnostic solutions.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Argentina's lateral flow assays market is valued at USD 13.3 million in 2025, with projected growth to USD 17.0 million by 2030, representing a steady 5% CAGR driven by increasing healthcare modernization.
Rising demand for rapid diagnostic solutions across Argentine healthcare facilities and clinical laboratories is accelerating the adoption of lateral flow assays for faster patient outcomes and reduced testing turnaround times.
Argentina's expanding healthcare infrastructure and investment in diagnostic capabilities are creating favorable conditions for lateral flow assay market penetration across both urban and emerging regional markets.
Growing number of private and public clinical laboratories in Argentina are increasingly integrating lateral flow assay technologies to enhance diagnostic efficiency and meet rising patient demand for accessible testing.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Provides rapid lateral flow diagnostics through its BinaxNOW and other rapid-testing platforms, including digitally read LFA formats such as BinaxNOW Influenza A & B Card 2 for the DIGIVAL platform. | Enables rapid decentralized testing, supports objective digital interpretation, and provides results within minutes for point-of-care and other testing settings. |
|
|
Develops lateral flow immunochromatographic tests for rapid diagnostics and is expanding access to large-scale LFA manufacturing through its strategic relationship with Sapphiros. Roche's SARS-CoV-2 Rapid Antigen Test 2.0 also incorporates digitally readable test identification. | Supports rapid decentralized testing, enables digital traceability of individual tests, and strengthens access to scalable LFA manufacturing capacity. |
|
|
Through Abcam, provides LFA-related assay development tools, including a Universal Lateral Flow Assay Kit and antibody-conjugation technologies specifically applicable to LFA development. | Supports LFA assay development and optimization by enabling antibody labeling, conjugation with gold/fluorescent nanoparticles, and reproducible test development. |
|
|
Provides the BD Veritor Plus System, combining a rapid point-of-care analyzer with lateral-flow-based assays for respiratory infections including influenza A/B, RSV and Group A Strep. | Provides rapid, objective digital results, supports decentralized testing, and enables multiple assays on a common point-of-care platform. |
|
|
Offers QUICKVUE rapid lateral-flow tests and the SOFIA platform, which uses fluorescent immunoassay/lateral-flow technology for rapid point-of-care testing across infectious and other diagnostic applications. | Enables fast testing in point-of-care and laboratory settings, while SOFIA provides automated and objective interpretation to improve testing efficiency. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SEXUALLY TRANSMITTED INFECTION TESTING (Disease Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 8% from 2025 to 2030 |
| Largest Segment | KITS & REAGENTS (Product) |
| Market Size Base Year (Billions) | ~USD 8.52 (2025) |
| Revenue Forecast (Billions) | ~USD 12.52 (2030) |
| Segments Covered | Product, Application, Type, Disease Type, Technique |
5 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| DIAGNOSTIC LABORATORIES | 3.58 | 3.75 | 3.93 | 4.14 | 4.36 | 4.61 | 4.88 | 5.18 | 5.7 |
| HOME CARE SETTINGS | 3.82 | 4.02 | 4.23 | 4.47 | 4.74 | 5.04 | 5.36 | 5.72 | 6.2 |
| HOSPITALS & CLINICS | 6.98 | 7.22 | 7.49 | 7.78 | 8.1 | 8.46 | 8.85 | 9.27 | 4.4 |
| OTHER END USERS | 0.33 | 0.34 | 0.35 | 0.36 | 0.38 | 0.39 | 0.41 | 0.42 | 3.7 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 0.23 | 0.23 | 0.24 | 0.25 | 0.25 | 0.26 | 0.27 | 0.28 | 3.3 |
| TOTAL | 14.94 | 15.57 | 16.24 | 16.99 | 17.83 | 18.75 | 19.77 | 20.87 | 5.1 |
Argentina's lateral flow assays market is estimated at USD 13.3 million in 2025.
Argentina's lateral flow assays market is projected to reach USD 17.0 million by 2030.
Argentina's lateral flow assays market is growing at a CAGR of 5.0% from 2025 to 2030.
Argentina's market growth is driven by increasing adoption of point-of-care diagnostics, healthcare infrastructure investments, and rising awareness of infectious disease screening.
Argentina's 5.0% CAGR is more conservative than the global 8.0% CAGR, reflecting regional market maturity and adoption patterns specific to Latin America.
The study focused on estimating the current market size of the global lateral flow assays market. Exhaustive secondary research was done to collect information on the lateral flow assays industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the lateral flow assays market.
The four steps involved in estimating the market size are:
The secondary research process involves the widespread use of secondary sources, directories, databases, white papers, annual reports, investor presentations, SEC filings of companies, and publications from government sources [such as the US Food and Drug Administration, World Health Organization (WHO), ??Centers for Disease Control and Prevention, International Organization for Standardization (ISO), Agency for Healthcare Research and Quality] to identify and collect information for the global lateral flow assays market study. It was also used to obtain key information on players and market classification & segmentation, aligned with industry trends, down to the most granular level, along with key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources on the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and other key executives from key companies and organizations in the lateral flow assays market. Primary demand-side sources include hospitals, clinics, diagnostic laboratories, and pharmaceutical and biotechnology companies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

Note 1: Other designations include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2025, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global lateral flow assays market. All the major service providers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. The global lateral flow assays market was split into various segments and subsegments based on:
The above data was consolidated with detailed inputs and analysis from MarketsandMarkets and presented in this report.

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data were triangulated by studying various factors and trends from both the demand and supply sides.
Lateral flow assays, or lateral flow immunochromatographic assays, are simple-to-use diagnostic devices to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals or contaminants in water supplies, without requiring specialized equipment.
MarketsandMarkets offers the following customizations for this market report.
Country Information
Company profiles
Product Analysis
Full forecast, segment splits, and company analysis for all Lateral Flow Assays Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report